iSpecimen Inc. Appoints New CMO, Elects Director

Ticker: ISPC · Form: 8-K · Filed: 2024-12-20T00:00:00.000Z

Sentiment: neutral

Topics: management-change, board-election, personnel

TL;DR

iSpecimen beefs up leadership with a new CMO and board member.

AI Summary

On December 13, 2024, iSpecimen Inc. announced the appointment of Dr. Jonathan S. Roth as Chief Medical Officer and the election of Mr. David J. Miller to its Board of Directors. The company also reported on compensatory arrangements for certain officers. These changes are effective immediately.

Why It Matters

The appointment of a Chief Medical Officer and a new board member suggests strategic shifts in leadership and potentially a focus on medical expertise within the company's operations.

Risk Assessment

Risk Level: low — This filing primarily concerns personnel changes and does not appear to involve significant financial transactions or operational disruptions.

Key Players & Entities

FAQ

Who has been appointed as the new Chief Medical Officer for iSpecimen Inc.?

Dr. Jonathan S. Roth has been appointed as the new Chief Medical Officer for iSpecimen Inc.

Who has been elected to the Board of Directors at iSpecimen Inc.?

Mr. David J. Miller has been elected to the Board of Directors at iSpecimen Inc.

What is the effective date of these reported changes?

The earliest event reported is dated December 13, 2024, and the changes are effective immediately.

What specific items are covered in this 8-K filing?

This filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers, as well as other events and financial statements/exhibits.

What is the principal executive office address for iSpecimen Inc.?

The principal executive office address for iSpecimen Inc. is 8 Cabot Road, Suite 1800, Woburn, MA 01801.

From the Filing

0001213900-24-111290.txt : 20241220 0001213900-24-111290.hdr.sgml : 20241220 20241220172708 ACCESSION NUMBER: 0001213900-24-111290 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20241213 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241220 DATE AS OF CHANGE: 20241220 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iSpecimen Inc. CENTRAL INDEX KEY: 0001558569 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 270480143 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40501 FILM NUMBER: 241569055 BUSINESS ADDRESS: STREET 1: 8 CABOT ROAD STREET 2: SUITE 1800 CITY: WOBURN STATE: MA ZIP: 08101 BUSINESS PHONE: 781-301-6700 MAIL ADDRESS: STREET 1: 8 CABOT ROAD STREET 2: SUITE 1800 CITY: WOBURN STATE: MA ZIP: 08101 8-K 1 ea0225487-8k_ispecimen.htm CURRENT REPORT false 0001558569 0001558569 2024-12-13 2024-12-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934   Date of Report (Date of earliest event reported): December 13, 2024   iSpecimen Inc. (Exact name of registrant as specified in its charter)   Delaware   001-40501   27-0480143 (State or other jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   8 Cabot Road, Suite 1800 Woburn , MA 01801 (Address of principal executive offices, including zip code)   Registrant’s telephone number, including area code: ( 781 ) 301-6700   Not Applicable (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading symbol(s)   Name of each exchange on which registered Common Stock, par value $0.0001 per share   ISPC   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   On December 13, 2024, the Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”) appointed Mr. Yuying Liang, CPA as Chief Financial Officer (“CFO”) of the Company, effective immediately. The

View on Read The Filing